Industry experts from the healthcare segment made their remarks post-budget 2025. The budget strengthens India's commitment to health innovation, inclusive growth and improved access to nutrition. The exemption of around 40 life-saving drugs from...
C2 PHARMA has disclosed the approval of a Certificate of Suitability (CEP) for Oxybuprocaine Hydrochloride from the European Directorate for the Quality of Medicines and Health Care (EDQM). Oxybuprocaine Hydrochloride is presently accessible to...
Apogee Therapeutics, Inc., a biotechnology firm in the clinical stage, announced that the initial patient has received treatment in Part B of the phase 2 APEX clinical trial of APG777 for individuals with moderate-to-severe atopic dermatitis (AD)...
Jupiter Neurosciences Inc., a pharmaceutical company in the clinical stage, is developing JOTROL, a patented platform based on resveratrol, and has reached an agreement with Catalent Pharma Solutions LLC to produce JOTROL softgel capsules to...
Akums Drugs and Pharmaceuticals, a leader in contract development and manufacturing, has launched Dapagliflozin + Pioglitazone tablets; an advanced combination therapy designed to tackle the growing challenge of diabetes management...
Ameera Shah’s Metropolis Healthcare Limited, the second-largest and most esteemed pathology laboratory chain in India, announced its partnership with Roche Diagnostics India and surrounding regions to launch the self-sampling human papillomavirus...
Tasso Inc., the premier provider of patient-focused, clinical-grade blood collection solutions, along with ARUP Laboratories, the largest nonprofit clinical and academic reference lab in the U.S., announced their partnership to create and...
Datopotamab deruxtecan (Dato-DXd) has received a recommendation for approval in the European Union (EU) to treat adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast...
Vanda Pharmaceuticals Inc. and AnaptysBio, Inc. announced an exclusive worldwide licensing agreement for the development and marketing of imsidolimab (IL-36R antagonist mAb), which has successfully finished two registration-supporting global Phase...
Inhalon Biopharma, Inc. (Inhalon), a clinical-stage firm developing a pioneering inhaled antibody platform for addressing acute respiratory infections (ARI), has today revealed the successful conclusion of IND-enabling studies for its respiratory...